摘要
目的:分析乳腺癌组织环氧化酶-2(COX-2)蛋白、人表皮生长因子受体2(c-erbB-2)、突变型P53蛋白、血管内皮生长因子C(VEGF-C)蛋白表达及其与临床病理参数和预后的关系。方法:选取2017年3月至2019年5月到我院就诊103例乳腺癌患者的手术切除标本。免疫组化法测定患者入组时的COX-2、c-erbB-2、P53、VEGF-C蛋白阳性率;比较上述各指标水平与患者TNM分期、分化程度等病理参数的关系;随访患者术后3年生存资料,Kaplan-Meier分析COX-2、c-erbB-2、P53、VEGF-C蛋白水平对预后生存的影响。结果:患者TNM分期、分化程度与COX-2阳性相关(P<0.05);肿瘤直径≥3cm、淋巴结转移与c-erbB-2阳性相关(P<0.05);TNM分期、分化程度、淋巴结转移与P53阳性相关(P<0.05);淋巴结转移与VEGF-C阳性相关(P<0.05)。103例患者随访3年,随访率为100%,截止至2022年5月死亡20例(19.42%),存活83例(80.58%);根据死亡情况将阳性患者分为存活亚组及死亡亚组,死亡亚组患者入组时的组化评分均明显高于存活亚组(P<0.05)。Log-rank χ^(2)检验显示随访3年P53、VEGF-C阳性及阴性的累积存活率比较差异有统计学意义(χ^(2)=14.000、5.206,P均<0.05);COX-2、c-erbB-2阳性及阴性患者的累积存活率比较差异无统计学意义(χ^(2)=1.761、2.830,P=0.184、0.093)。结论:乳腺癌组织中COX-2、c-erbB-2、P53、VEGF-C蛋白阳性率与TNM分期、淋巴结转移、分化程度等病理参数相关,在患者预后评估中具有一定指导意义。
Objective:To analyze the expressions of cyclooxygenase-2(COX-2)protein,human epidermal growth factor receptor 2(c-erbB-2),mutant P53 protein,and vascular endothelial growth factor c(VEGF-C)protein in breast cancer tissues and their relationships with clinicopathological parameters and prognosis.Methods:The surgical resection specimens of 103 patients with breast cancer who were treated in the hospital from March 2017 to May 2019 were selected.The protein positive rates of COX-2,c-erbB-2,P53 and VEGF-C were determined by immunohistochemistry.The relationships of levels of the above indicators with pathological parameters such as TNM staging and differentiation degree were compared.The survival data of patients at 3 years after surgery were followed up,and Kaplan-Meier method was used to analyze the effects of protein levels of COX-2,c-erbB-2,P53 and VEGF-C on the prognosis survival.Results:TNM staging and differentiation degree were correlated with positive COX-2(P<0.05).Tumor diameter≥3cm and lymph node metastasis were associated with positive c-erbB-2(P<0.05).TNM staging,differentiation degree and lymph node metastasis were correlated with positive P53(P<0.05).Lymph node metastasis was related to positive VEGF-C(P<0.05).103 patients were followed up for 3 years,with a follow-up rate of 100%;20 patients died(19.42%)and 83 patients survived(80.58%)as of May 2022;positive patients were divided into survival and death subgroups according to the death status,and the histochemical scores of patients in the death subgroup were significantly higher than those in the survival subgroup at enrollment(P<0.05).Log-rank χ^(2) test showed that there were statistical differences in the cumulative survival rates between patients with positive and negative P53 and VEGF-C after 3 years of follow-up(χ^(2)=14.000,5.206,all P<0.05).There were no statistically significant differences in the cumulative survival rates between patients with positive and negative COX-2 and c-erbB-2(χ^(2)=1.761,2.830,P=0.184,0.093).Conclusion:The prot
作者
李瑞青
张杰
LI Ruiqing;ZHANG Jie(The Affiliated Hospital of Yangzhou University,Jiangsu Yangzhou 225000,China)
出处
《河北医学》
CAS
2023年第5期747-751,共5页
Hebei Medicine
基金
江苏省卫生健康委科研项目,(编号:M2021039)。
